Literature DB >> 17430108

Indoleamine 2,3-dioxygenase in materno-fetal interaction.

Peter Sedlmayr1.   

Abstract

The mechanism of maternal immunotolerance of the semiallogeneic fetus has been a matter of intense investigation. The tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) is reported to be critically implicated. This article discusses findings pertaining to the role of IDO in pregnancy, its location at the feto-maternal interface, systemic induction of IDO in pregnancy and the association of IDO to spontaneous abortion and preeclampsia. Whereas there is a large body of evidence supporting the relevance of IDO as a key immunoregulatory factor in feto-maternal tolerance, open questions remain concerning as to its role.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17430108     DOI: 10.2174/138920007780362491

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  5 in total

1.  Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis.

Authors:  Weiping Hou; Suzhi Li; Yinping Wu; Xiang Du; Fahuan Yuan
Journal:  Clin Exp Immunol       Date:  2009-03-11       Impact factor: 4.330

Review 2.  Changing the face of kynurenines and neurotoxicity: therapeutic considerations.

Authors:  Zsuzsanna Bohár; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  Int J Mol Sci       Date:  2015-04-29       Impact factor: 5.923

Review 3.  AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" a translational review and therapeutic perspectives.

Authors:  Waldemar A Turski; Artur Wnorowski; Gabrielle N Turski; Christopher A Turski; Lechoslaw Turski
Journal:  Restor Neurol Neurosci       Date:  2020       Impact factor: 2.406

4.  Association between endometrial indoleamine 2,3-dioxygenase expression level and pregnancy outcomes in women undergoing first in vitro fertilization treatment.

Authors:  Su Liu; Ling Hong; Yuye Li; Ruochun Lian; Xiaohui Wang; Yong Zeng
Journal:  BMC Pregnancy Childbirth       Date:  2021-01-07       Impact factor: 3.007

5.  Macrophage Migration Inhibitory Factor (MIF) Prevents Maternal Death, but Contributes to Poor Fetal Outcome During Congenital Toxoplasmosis.

Authors:  Angelica O Gomes; Bellisa F Barbosa; Priscila S Franco; Mayara Ribeiro; Rafaela J Silva; Paula S G Gois; Karine C Almeida; Mariana B Angeloni; Andressa S Castro; Pâmela M Guirelli; João V Cândido; Javier E L Chica; Neide M Silva; Tiago W P Mineo; José R Mineo; Eloisa A V Ferro
Journal:  Front Microbiol       Date:  2018-05-08       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.